Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials

Lung Cancer

Volumn 67, Issue 1, 2010, Pages 86-92

  Gridelli, Cesare ^a   Morabito, Alessandro ^b   Gebbia, Vittorio ^c   Mencoboni, Manlio ^d   Carrozza, Francesco ^e   Viganò, Maria Grazia ^f   Verusio, Claudio ^g   Bollina, Roberto ^h   Mattioli, Rodolfo ⁱ   Valerio, Maria Rosaria ^c   Valmadre, Giuseppe ^j   Maione, Paolo ^a   Rossi, Antonio ^a   Cascone, Tina ^k   Morgillo, Floriana ^k   Di Maio, Massimo ^b   Piccirillo, Maria Carmela ^b   Gallo, Ciro ^l   Perrone, Francesco ^b   Ciardiello, Fortunato ^k  

^a Oncologia Medica   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d VILLA SCASSI HOSPITAL   (Italy)

^e Ospedale A Cardarelli   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g Oncologia Medica   (Italy)

^h S Giuseppe Hospital   (Italy)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

^j DHOncologico   (Italy)

^k Oncologia Medica   (Italy)

^l SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

Cetuximab; Elderly patients; Gemcitabine; NSCLC; PS2 patients

Indexed keywords

CETUXIMAB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRY SKIN; EDEMA; FATIGUE; FEMALE; FOLLICULITIS; HAIR LOSS; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LOADING DRUG DOSE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; THROMBOCYTE DISORDER;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71849107743     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.021     Document Type: Article

References (33)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. SEER Cancer Statistics Review 1975-2004. http://www.seer.cancer.gov.
3. Gridelli C., Aapro M., Ardizzoni A., Balducci L., De Marinis F., Kelly K., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an International Expert Panel. J Clin Oncol 23 (2005) 3125-3137
4. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
5. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
6. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
7. ASCO Special Article. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15:2996-3018.
8. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2001; 12:1049-1050.
9. Bunn Jr. P.A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol 20 Suppl. 18 (2002) 23S-33S
10. Ferreira C.G., Huisman C., and Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 41 (2002) 57-77
11. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8 (2001) 3-9
12. Ciardiello F., and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358 (2008) 1160-1174
13. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 (2003) 2787-2799
14. Baselga J., Pfister D., Cooper M.R., Cohen R., Burtness B., Bos M., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18 (2000) 904-914
15. Thienelt C.D., Bunn Jr. P.A., Hanna N., Rosenberg A., Needle M.N., Long M.E., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23 (2005) 8786-8793
16. Robert F., Blumenschein G., Herbst R.S., Fossella F.V., Tseng J., Saleh M.N., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 9089-9096
17. Kim E.S., Mauer A.M., Tran H.T., Liu D., Gladish G., Dicke K., et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol 22 (2003) [abstr 2581]
18. Raben D., Helfrich B., Chan D.C., Ciardiello F., Zhao L., Franklin W., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11 (2005) 795-805
19. Normanno N., Bianco C., De Luca A., Maiello M.R., and Salomon D.S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10 (2003) 1-21
20. Simon R., Wittes R.E., and Ellenberg S.S. Randomized phase II clinical trials. Cancer Treat Rep 69 (1985) 1375-1381
21. Hanna N., Lilenbaum R., Ansari R., Lynch T., Govindan R., Jänne P.A., et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24 (2006) 5253-5258
22. Butts C.A., Bodkin D., Middleman E.L., Englund C.W., Ellison D., Alam Y., et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer. J Clin Oncol 25 (2007) 5777-5784
23. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19 (2008) 362-369
24. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Robert H., et al. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thor Oncol 2 (2007) S340 [abstr B3-03]
25. Pirker R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., Park K., et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26 (2008) [ASCO Annual Meeting Proceedings, abstr 3]
26. Tsuchihashi Z., khambata-Ford S., Hanna N., and Jänne P.A. Responsiveness to cetuximab without mutation in EGFR. N Engl J Med 353 (2005) 208-209
27. Steiner P., Joynes C., Bassi R., Wang S., Tonra J.R., Hadari Y.R., et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 13 (2007) 1540-1551
28. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
29. Hirsch F., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced nonsmall- cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
30. Mukohara T., Engelman J.A., Hanna N.H., Yeap B.Y., Kobayashi S., Lindeman N., et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97 (2005) 1185-1194
31. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
32. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008) 962-972
33. Lièvre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995